Ulobetasol propionate
Appearance
(Redirected from Ulobetasol Propionate)
![]() | |
Clinical data | |
---|---|
Trade names | Ultravate, Lexette, Bryhali |
Other names | Halobetasol propionate, halobetasol propionate (USAN US) |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a601060 |
Routes of administration | Topical |
Drug class | Corticosteroid; Glucocorticoid |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.211.977 |
Chemical and physical data | |
Formula | C25H31ClF2O5 |
Molar mass | 484.96 g·mol−1 |
3D model (JSmol) | |
| |
|
Ulobetasol propionate, also known as halobetasol propionate and sold under the brand name Ultravate among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.
It was patented in 1975 and approved for medical use in 1990.[2][3]
References
[edit]- ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
- ^ "Ultravate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 29 April 2020.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 487. ISBN 9783527607495.